Baxter International has launched its next-generation airway clearance system, The Vest advanced pulmonary experience (APX) system, aimed at supporting therapy for individuals with chronic lung conditions.
Revealed at the North American Cystic Fibrosis Conference, the system incorporates airflow technology and introduces new features for improved patient comfort and usability.
The Vest APX system is designed to assist daily therapy for both adults and children suffering from chronic lung conditions, as well as retained secretions.
It builds upon the established airflow technology, integrating feedback from clinicians and patients to advance the comfort and functionality of the device.
Chronic lung conditions such as cystic fibrosis and bronchiectasis often lead to mucus accumulation in the lungs, which can cause inflammation and infections.
The Vest APX system employs high-frequency chest wall oscillation (HFCWO) technology, which aids in loosening mucus from the bronchial walls, facilitating the movement of secretions to larger airways for removal.
The system provides added comfort and features unique designs providing an option to patients to select from a wide selection of new garment colours and designs.
It also has a user-friendly navigation on a touchscreen making it easy for patients and caregivers to start therapy.
Baxter Front Line Care president Jim O’Connell said: “Many patients who are prescribed this therapy use it multiple times a day, every day.
“With that in mind, it was very important for us to design a solution that fits seamlessly into a patient’s daily routine. The Vest APX System offers next-level comfort, ease of use and portability, all while maintaining the performance patients and caregivers have depended on for years.”
The company’s foray into the non-invasive respiratory health market began with the acquisition of Hillrom in December 2021. Hillrom's HFCWO technology is supported by more than 60 clinical studies.
Earlier this year, the Vest APX system received 510(k) clearance from the US Food and Drug Administration.
Baxter announced last month that it would divest its kidney care segment to global investment company Carlyle in a $3.5bn transaction.
